Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • Search results for:
    • covid 19
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
DoD - Moderna, COVID-19, Vaccine Supply Agreement
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Biotechnology company
Government
Vaccine
Preclinical
Commercialization
UK Government - Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
2021
Government
Multinational pharmaceutical company
Drug
Late clinical (Phase 3)
Commercialization

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [qs] => covid 19
        )

    [filters] => Array
        (
            [text_search] => covid 19
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [post__in] => Array
                (
                    [0] => 3436
                    [1] => 3435
                    [2] => 3434
                    [3] => 3433
                    [4] => 3431
                    [5] => 3430
                    [6] => 3428
                    [7] => 3427
                    [8] => 3426
                    [9] => 3424
                    [10] => 3422
                    [11] => 3421
                    [12] => 3420
                    [13] => 3372
                    [14] => 3371
                    [15] => 3370
                    [16] => 3368
                    [17] => 3366
                    [18] => 3364
                    [19] => 3363
                    [20] => 3361
                    [21] => 3360
                    [22] => 3356
                    [23] => 3354
                    [24] => 3352
                    [25] => 3221
                    [26] => 3220
                    [27] => 3219
                    [28] => 3218
                    [29] => 3217
                    [30] => 3216
                    [31] => 3215
                    [32] => 2956
                    [33] => 2961
                    [34] => 2965
                    [35] => 2947
                    [36] => 2960
                    [37] => 2964
                    [38] => 2958
                    [39] => 2949
                    [40] => 2957
                    [41] => 2962
                    [42] => 2945
                    [43] => 2909
                    [44] => 2908
                    [45] => 2907
                    [46] => 2893
                    [47] => 2892
                    [48] => 2890
                    [49] => 2889
                    [50] => 2888
                    [51] => 2886
                    [52] => 2885
                    [53] => 2824
                    [54] => 2823
                    [55] => 2822
                    [56] => 2821
                    [57] => 2820
                    [58] => 2819
                    [59] => 2744
                    [60] => 2749
                    [61] => 2748
                    [62] => 2740
                    [63] => 2743
                    [64] => 2742
                    [65] => 2741
                    [66] => 2739
                    [67] => 2738
                    [68] => 2737
                    [69] => 2736
                    [70] => 2735
                    [71] => 2734
                    [72] => 2543
                    [73] => 2540
                    [74] => 2541
                    [75] => 2542
                    [76] => 2544
                    [77] => 2545
                    [78] => 2546
                    [79] => 2547
                    [80] => 2548
                    [81] => 2549
                    [82] => 2553
                    [83] => 2554
                    [84] => 2457
                    [85] => 2459
                    [86] => 2460
                    [87] => 2461
                    [88] => 2462
                    [89] => 2463
                    [90] => 2464
                    [91] => 2465
                    [92] => 2466
                    [93] => 2467
                    [94] => 2470
                    [95] => 2472
                    [96] => 2473
                    [97] => 2474
                    [98] => 2475
                    [99] => 2476
                    [100] => 2477
                    [101] => 2478
                    [102] => 2479
                    [103] => 2480
                    [104] => 2481
                    [105] => 2482
                    [106] => 2483
                    [107] => 2471
                    [108] => 2454
                    [109] => 2452
                    [110] => 2450
                    [111] => 2449
                    [112] => 2448
                    [113] => 2445
                    [114] => 2444
                    [115] => 2443
                    [116] => 2442
                    [117] => 2441
                    [118] => 2440
                    [119] => 2425
                    [120] => 2426
                    [121] => 2424
                    [122] => 2422
                    [123] => 3436
                    [124] => 3435
                    [125] => 3434
                    [126] => 3433
                    [127] => 3431
                    [128] => 3430
                    [129] => 3428
                    [130] => 3427
                    [131] => 3426
                    [132] => 3424
                    [133] => 3422
                    [134] => 3421
                    [135] => 3420
                    [136] => 3372
                    [137] => 3371
                    [138] => 3370
                    [139] => 3368
                    [140] => 3366
                    [141] => 3364
                    [142] => 3363
                    [143] => 3361
                    [144] => 3360
                    [145] => 3356
                    [146] => 3354
                    [147] => 3352
                    [148] => 3221
                    [149] => 3220
                    [150] => 3219
                    [151] => 3218
                    [152] => 3217
                    [153] => 3216
                    [154] => 3215
                    [155] => 2909
                    [156] => 2908
                    [157] => 2907
                    [158] => 2893
                    [159] => 2892
                    [160] => 2890
                    [161] => 2889
                    [162] => 2888
                    [163] => 2886
                    [164] => 2885
                    [165] => 2744
                    [166] => 2749
                    [167] => 2748
                    [168] => 2740
                    [169] => 2743
                    [170] => 2742
                    [171] => 2741
                    [172] => 2739
                    [173] => 2738
                    [174] => 2737
                    [175] => 2736
                    [176] => 2735
                    [177] => 2734
                    [178] => 2543
                    [179] => 2540
                    [180] => 2541
                    [181] => 2542
                    [182] => 2544
                    [183] => 2545
                    [184] => 2546
                    [185] => 2547
                    [186] => 2548
                    [187] => 2549
                    [188] => 2553
                    [189] => 2554
                    [190] => 2457
                    [191] => 2459
                    [192] => 2460
                    [193] => 2461
                    [194] => 2462
                    [195] => 2463
                    [196] => 2464
                    [197] => 2465
                    [198] => 2466
                    [199] => 2467
                    [200] => 2470
                    [201] => 2472
                    [202] => 2473
                    [203] => 2474
                    [204] => 2475
                    [205] => 2476
                    [206] => 2477
                    [207] => 2478
                    [208] => 2479
                    [209] => 2480
                    [210] => 2481
                    [211] => 2482
                    [212] => 2483
                    [213] => 2471
                    [214] => 3406
                    [215] => 3304
                    [216] => 3127
                    [217] => 3126
                    [218] => 3125
                    [219] => 3124
                    [220] => 3123
                    [221] => 3122
                    [222] => 3121
                    [223] => 3120
                    [224] => 3119
                    [225] => 2947
                    [226] => 2873
                    [227] => 2872
                    [228] => 2870
                    [229] => 2869
                    [230] => 2868
                    [231] => 2867
                    [232] => 2865
                    [233] => 2824
                    [234] => 2823
                    [235] => 2822
                    [236] => 2454
                    [237] => 2452
                    [238] => 2450
                    [239] => 2449
                    [240] => 2448
                    [241] => 2445
                    [242] => 2444
                    [243] => 2443
                    [244] => 2442
                    [245] => 2441
                    [246] => 2440
                    [247] => 2425
                    [248] => 2426
                    [249] => 2424
                    [250] => 2422
                )

        )

    [text_agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [s] => covid 19
        )

    [text_provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [s] => covid 19
        )

    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => 
    [text_agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => covid 19
                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => covid 19
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 2
                    [search_terms] => Array
                        (
                            [0] => covid
                            [1] => 19
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
                            [1] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
                        )

                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT DISTINCT   wpry_posts.* FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON (a.post_id = wpry_posts.ID) LEFT JOIN wpry_postmeta AS b ON (((b.meta_id = a.meta_id + @@auto_increment_increment)) AND ((b.meta_key LIKE CONCAT('\_', a.meta_key)))) LEFT JOIN wpry_posts AS c ON ((c.post_name = b.meta_value) AND (c.post_type = 'acf-field') AND ((c.post_content LIKE '%:"text"%') OR (c.post_content LIKE '%:"textarea"%') OR (c.post_content LIKE '%:"wysiwyg"%') OR (c.post_content LIKE '%:"checkbox"%')))  WHERE 1=1  AND (((b.meta_id IS NOT NULL) AND (c.ID IS NOT NULL) AND (a.meta_value LIKE '%covid%') AND (a.meta_value LIKE '%19%')) OR (((wpry_posts.post_title LIKE '%covid%') OR (wpry_posts.post_content LIKE '%covid%') OR (wpry_posts.post_excerpt LIKE '%covid%')) AND ((wpry_posts.post_title LIKE '%19%') OR (wpry_posts.post_content LIKE '%19%') OR (wpry_posts.post_excerpt LIKE '%19%'))))  AND wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')  ORDER BY wpry_posts.post_title ASC 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 2438
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:43:39
                            [post_date_gmt] => 2021-01-19 06:43:39
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:40:15
                            [post_modified_gmt] => 2021-07-20 13:40:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 2882
                            [post_author] => 6
                            [post_date] => 2021-05-14 14:03:29
                            [post_date_gmt] => 2021-05-14 14:03:29
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:54:05
                            [post_modified_gmt] => 2021-07-20 13:54:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 2446
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:42:42
                            [post_date_gmt] => 2021-01-19 09:42:42
                            [post_content] => 
                            [post_title] => DoD - Moderna, COVID-19, Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => award-contract-no-w911qy20c0100-by-and-between-modernatx-inc-and-the-department-of-defense
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:27:18
                            [post_modified_gmt] => 2021-07-20 13:27:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2446
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 2538
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:41:11
                            [post_date_gmt] => 2021-03-12 13:41:11
                            [post_content] => 
                            [post_title] => European Commision - Astrazeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => advance-purchase-agreement-for-the-production-purchase-and-supply-of-a-covid-19-vaccine-in-the-european-union-with-astrazeneca
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:25:09
                            [post_modified_gmt] => 2021-07-20 13:25:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2538
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 2468
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:15:43
                            [post_date_gmt] => 2021-02-25 15:15:43
                            [post_content] => 
                            [post_title] => European Commision - Curevac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => advance-purchase-agreement-for-the-development-production-advance-purchase-and-supply-of-a-covid-19-vaccine-for-eu-member-states-with-curevac
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:23:58
                            [post_modified_gmt] => 2021-07-20 13:23:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2468
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 3419
                            [post_author] => 6
                            [post_date] => 2021-07-01 01:45:34
                            [post_date_gmt] => 2021-07-01 01:45:34
                            [post_content] => 
                            [post_title] => Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 01:47:20
                            [post_modified_gmt] => 2021-07-01 01:47:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3419
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 3348
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:13:40
                            [post_date_gmt] => 2021-06-30 13:13:40
                            [post_content] => 
                            [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:13:40
                            [post_modified_gmt] => 2021-06-30 13:13:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3348
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3213
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:04:36
                            [post_date_gmt] => 2021-06-28 12:04:36
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:04:36
                            [post_modified_gmt] => 2021-06-28 12:04:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3213
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 2817
                            [post_author] => 5
                            [post_date] => 2021-04-16 11:58:45
                            [post_date_gmt] => 2021-04-16 11:58:45
                            [post_content] => 
                            [post_title] => Regeneron - ATI, COVID-19 Antibodies Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:55:11
                            [post_modified_gmt] => 2021-07-20 13:55:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 2420
                            [post_author] => 5
                            [post_date] => 2020-12-14 14:59:07
                            [post_date_gmt] => 2020-12-14 14:59:07
                            [post_content] => 
                            [post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:29:49
                            [post_modified_gmt] => 2021-07-20 13:29:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2420
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 2943
                            [post_author] => 6
                            [post_date] => 2021-05-28 13:48:32
                            [post_date_gmt] => 2021-05-28 13:48:32
                            [post_content] => 
                            [post_title] => UK Government - AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:26:21
                            [post_modified_gmt] => 2021-07-20 13:26:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2943
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 2732
                            [post_author] => 5
                            [post_date] => 2021-03-23 15:54:07
                            [post_date_gmt] => 2021-03-23 15:54:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:54:35
                            [post_modified_gmt] => 2021-07-20 13:54:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2732
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 2455
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:19:51
                            [post_date_gmt] => 2021-02-25 15:19:51
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-20 13:55:49
                            [post_modified_gmt] => 2021-07-20 13:55:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2455
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 13
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 2438
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:43:39
                    [post_date_gmt] => 2021-01-19 06:43:39
                    [post_content] => 
                    [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-20 13:40:15
                    [post_modified_gmt] => 2021-07-20 13:40:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 13
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 1fc2d19f378284cf7496bf5ba612c2e6
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => covid 19
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => covid 19
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 2
                    [search_terms] => Array
                        (
                            [0] => covid
                            [1] => 19
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
                            [1] => wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}'
                        )

                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT DISTINCT   wpry_posts.* FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON (a.post_id = wpry_posts.ID) LEFT JOIN wpry_postmeta AS b ON (((b.meta_id = a.meta_id + @@auto_increment_increment)) AND ((b.meta_key LIKE CONCAT('\_', a.meta_key)))) LEFT JOIN wpry_posts AS c ON ((c.post_name = b.meta_value) AND (c.post_type = 'acf-field') AND ((c.post_content LIKE '%:"text"%') OR (c.post_content LIKE '%:"textarea"%') OR (c.post_content LIKE '%:"wysiwyg"%') OR (c.post_content LIKE '%:"checkbox"%')))  WHERE 1=1  AND (((b.meta_id IS NOT NULL) AND (c.ID IS NOT NULL) AND (a.meta_value LIKE '%covid%') AND (a.meta_value LIKE '%19%')) OR (((wpry_posts.post_title LIKE '%covid%') OR (wpry_posts.post_content LIKE '%covid%') OR (wpry_posts.post_excerpt LIKE '%covid%')) AND ((wpry_posts.post_title LIKE '%19%') OR (wpry_posts.post_content LIKE '%19%') OR (wpry_posts.post_excerpt LIKE '%19%'))))  AND wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')  ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid 19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 1 WHEN wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' AND wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 2 WHEN wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' OR wpry_posts.post_title LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 3 WHEN wpry_posts.post_excerpt LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid 19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 4 WHEN wpry_posts.post_content LIKE '{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}covid 19{cedbfb97740b3a5b7ff53151167dd5ad105c25d52120ed62fbfef6561f6dc372}' THEN 5 ELSE 6 END), wpry_posts.post_date DESC 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 3436
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:48:49
                            [post_date_gmt] => 2021-07-01 03:48:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 11:01:08
                            [post_modified_gmt] => 2021-07-22 11:01:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 3435
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:45:58
                            [post_date_gmt] => 2021-07-01 03:45:58
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:45:58
                            [post_modified_gmt] => 2021-07-01 03:45:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3435
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 3434
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:44:18
                            [post_date_gmt] => 2021-07-01 03:44:18
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:44:18
                            [post_modified_gmt] => 2021-07-01 03:44:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3434
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 3433
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:41:21
                            [post_date_gmt] => 2021-07-01 03:41:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:41:21
                            [post_modified_gmt] => 2021-07-01 03:41:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3433
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 3431
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:38:49
                            [post_date_gmt] => 2021-07-01 03:38:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:38:49
                            [post_modified_gmt] => 2021-07-01 03:38:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3431
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 3430
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:27:51
                            [post_date_gmt] => 2021-07-01 03:27:51
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 13:58:20
                            [post_modified_gmt] => 2021-07-22 13:58:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3430
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 3428
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:24:00
                            [post_date_gmt] => 2021-07-01 03:24:00
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:24:00
                            [post_modified_gmt] => 2021-07-01 03:24:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3428
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3427
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:22:23
                            [post_date_gmt] => 2021-07-01 03:22:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:22:23
                            [post_modified_gmt] => 2021-07-01 03:22:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 3426
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:06:23
                            [post_date_gmt] => 2021-07-01 03:06:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:06:23
                            [post_modified_gmt] => 2021-07-01 03:06:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 3424
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:03:57
                            [post_date_gmt] => 2021-07-01 03:03:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:03:57
                            [post_modified_gmt] => 2021-07-01 03:03:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 3422
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:58:21
                            [post_date_gmt] => 2021-07-01 02:58:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 15:32:57
                            [post_modified_gmt] => 2021-07-22 15:32:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 3421
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:56:30
                            [post_date_gmt] => 2021-07-01 02:56:30
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 02:56:30
                            [post_modified_gmt] => 2021-07-01 02:56:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3421
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 3420
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:52:05
                            [post_date_gmt] => 2021-07-01 02:52:05
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 02:52:05
                            [post_modified_gmt] => 2021-07-01 02:52:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3420
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 3372
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:06:19
                            [post_date_gmt] => 2021-06-30 15:06:19
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 15:06:19
                            [post_modified_gmt] => 2021-06-30 15:06:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3372
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 3371
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:03:10
                            [post_date_gmt] => 2021-06-30 15:03:10
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 15:03:10
                            [post_modified_gmt] => 2021-06-30 15:03:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3371
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 3370
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:01:06
                            [post_date_gmt] => 2021-06-30 15:01:06
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 15:01:06
                            [post_modified_gmt] => 2021-06-30 15:01:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3370
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 3368
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:58:39
                            [post_date_gmt] => 2021-06-30 14:58:39
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:58:39
                            [post_modified_gmt] => 2021-06-30 14:58:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3368
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 3366
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:53:53
                            [post_date_gmt] => 2021-06-30 14:53:53
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:53:53
                            [post_modified_gmt] => 2021-06-30 14:53:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3366
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 3364
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:47:34
                            [post_date_gmt] => 2021-06-30 14:47:34
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:47:34
                            [post_modified_gmt] => 2021-06-30 14:47:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3364
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 3363
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:45:00
                            [post_date_gmt] => 2021-06-30 14:45:00
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:45:00
                            [post_modified_gmt] => 2021-06-30 14:45:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3363
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 3361
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:30:51
                            [post_date_gmt] => 2021-06-30 14:30:51
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:30:51
                            [post_modified_gmt] => 2021-06-30 14:30:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3361
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 3360
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:28:40
                            [post_date_gmt] => 2021-06-30 14:28:40
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:28:40
                            [post_modified_gmt] => 2021-06-30 14:28:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3360
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 3356
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:53:23
                            [post_date_gmt] => 2021-06-30 13:53:23
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:53:23
                            [post_modified_gmt] => 2021-06-30 13:53:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 3354
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:29:21
                            [post_date_gmt] => 2021-06-30 13:29:21
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:29:21
                            [post_modified_gmt] => 2021-06-30 13:29:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3354
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 3352
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:24:49
                            [post_date_gmt] => 2021-06-30 13:24:49
                            [post_content] => 
                            [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:24:49
                            [post_modified_gmt] => 2021-06-30 13:24:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3352
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 3221
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:23:49
                            [post_date_gmt] => 2021-06-28 12:23:49
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:23:49
                            [post_modified_gmt] => 2021-06-28 12:23:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 3220
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:22:09
                            [post_date_gmt] => 2021-06-28 12:22:09
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:22:09
                            [post_modified_gmt] => 2021-06-28 12:22:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 3219
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:19:29
                            [post_date_gmt] => 2021-06-28 12:19:29
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:19:29
                            [post_modified_gmt] => 2021-06-28 12:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 3218
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:16:20
                            [post_date_gmt] => 2021-06-28 12:16:20
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:16:20
                            [post_modified_gmt] => 2021-06-28 12:16:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 3217
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:14:37
                            [post_date_gmt] => 2021-06-28 12:14:37
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:14:37
                            [post_modified_gmt] => 2021-06-28 12:14:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 3216
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:11:22
                            [post_date_gmt] => 2021-06-28 12:11:22
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:11:22
                            [post_modified_gmt] => 2021-06-28 12:11:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 3215
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:07:55
                            [post_date_gmt] => 2021-06-28 12:07:55
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:07:55
                            [post_modified_gmt] => 2021-06-28 12:07:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-16 15:39:30
                            [post_modified_gmt] => 2021-06-16 15:39:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 2908
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:08:05
                            [post_date_gmt] => 2021-05-19 15:08:05
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 12:18:00
                            [post_modified_gmt] => 2021-07-21 12:18:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 2907
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:46:20
                            [post_date_gmt] => 2021-05-19 14:46:20
                            [post_content] => 
                            [post_title] => Novavax – CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 14:10:32
                            [post_modified_gmt] => 2021-07-22 14:10:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 2893
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:40:45
                            [post_date_gmt] => 2021-05-19 14:40:45
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 08:56:01
                            [post_modified_gmt] => 2021-06-21 08:56:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 2892
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:30:23
                            [post_date_gmt] => 2021-05-14 19:30:23
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 15:13:39
                            [post_modified_gmt] => 2021-06-02 15:13:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 2890
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:14:07
                            [post_date_gmt] => 2021-05-14 19:14:07
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 12:49:25
                            [post_modified_gmt] => 2021-06-08 12:49:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 2889
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:09:07
                            [post_date_gmt] => 2021-05-14 19:09:07
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 19:09:07
                            [post_modified_gmt] => 2021-05-14 19:09:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 2888
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:01:08
                            [post_date_gmt] => 2021-05-14 19:01:08
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-20 12:23:46
                            [post_modified_gmt] => 2021-05-20 12:23:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2888
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 2886
                            [post_author] => 6
                            [post_date] => 2021-05-14 18:21:24
                            [post_date_gmt] => 2021-05-14 18:21:24
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 18:21:24
                            [post_modified_gmt] => 2021-05-14 18:21:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2886
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 2885
                            [post_author] => 5
                            [post_date] => 2021-05-14 18:17:37
                            [post_date_gmt] => 2021-05-14 18:17:37
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 18:17:37
                            [post_modified_gmt] => 2021-05-14 18:17:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 2744
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:12:35
                            [post_date_gmt] => 2021-03-30 15:12:35
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:21:21
                            [post_modified_gmt] => 2021-05-17 13:21:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 2749
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:10:16
                            [post_date_gmt] => 2021-03-30 15:10:16
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:43:25
                            [post_modified_gmt] => 2021-06-01 09:43:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 2748
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:05:46
                            [post_date_gmt] => 2021-03-30 15:05:46
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2748
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:21:40
                            [post_modified_gmt] => 2021-05-17 13:21:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 2740
                            [post_author] => 5
                            [post_date] => 2021-03-30 14:54:54
                            [post_date_gmt] => 2021-03-30 14:54:54
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:21:50
                            [post_modified_gmt] => 2021-05-17 13:21:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2740
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 2743
                            [post_author] => 5
                            [post_date] => 2021-03-24 15:11:40
                            [post_date_gmt] => 2021-03-24 15:11:40
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:22:13
                            [post_modified_gmt] => 2021-05-17 13:22:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 2742
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:37:07
                            [post_date_gmt] => 2021-03-24 13:37:07
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 14:14:47
                            [post_modified_gmt] => 2021-07-22 14:14:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 2741
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:32:55
                            [post_date_gmt] => 2021-03-24 13:32:55
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:22:24
                            [post_modified_gmt] => 2021-05-17 13:22:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 2739
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:12:14
                            [post_date_gmt] => 2021-03-24 13:12:14
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:22:33
                            [post_modified_gmt] => 2021-05-17 13:22:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 2738
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:04:24
                            [post_date_gmt] => 2021-03-24 13:04:24
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 09:03:59
                            [post_modified_gmt] => 2021-06-09 09:03:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2738
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 2737
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:00:46
                            [post_date_gmt] => 2021-03-24 13:00:46
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:23:04
                            [post_modified_gmt] => 2021-05-17 13:23:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 2736
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:15:15
                            [post_date_gmt] => 2021-03-23 18:15:15
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:23:17
                            [post_modified_gmt] => 2021-05-17 13:23:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 2735
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:05:28
                            [post_date_gmt] => 2021-03-23 18:05:28
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:23:28
                            [post_modified_gmt] => 2021-05-17 13:23:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2735
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 2734
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:01:22
                            [post_date_gmt] => 2021-03-23 18:01:22
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 17:12:58
                            [post_modified_gmt] => 2021-06-07 17:12:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 2543
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:15:58
                            [post_date_gmt] => 2021-03-12 18:15:58
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:24:40
                            [post_modified_gmt] => 2021-05-17 13:24:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 2540
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:12:48
                            [post_date_gmt] => 2021-03-12 18:12:48
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 13:52:44
                            [post_modified_gmt] => 2021-07-07 13:52:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 2541
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:11:14
                            [post_date_gmt] => 2021-03-12 18:11:14
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 16:06:34
                            [post_modified_gmt] => 2021-05-28 16:06:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 2542
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:21:07
                            [post_date_gmt] => 2021-03-12 14:21:07
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 15:59:01
                            [post_modified_gmt] => 2021-05-28 15:59:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 2544
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:16:06
                            [post_date_gmt] => 2021-03-12 14:16:06
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:14
                            [post_modified_gmt] => 2021-05-17 13:25:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 2545
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:14:38
                            [post_date_gmt] => 2021-03-12 14:14:38
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:23
                            [post_modified_gmt] => 2021-05-17 13:25:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 2546
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:13:16
                            [post_date_gmt] => 2021-03-12 14:13:16
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:35
                            [post_modified_gmt] => 2021-05-17 13:25:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2546
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 2547
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:58:55
                            [post_date_gmt] => 2021-03-12 13:58:55
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 10:39:30
                            [post_modified_gmt] => 2021-07-21 10:39:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 2548
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:55:59
                            [post_date_gmt] => 2021-03-12 13:55:59
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 09:42:06
                            [post_modified_gmt] => 2021-06-04 09:42:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2548
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 2549
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:50:41
                            [post_date_gmt] => 2021-03-12 13:50:41
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:58
                            [post_modified_gmt] => 2021-05-17 13:25:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 2553
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:47:42
                            [post_date_gmt] => 2021-03-12 13:47:42
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 16:09:05
                            [post_modified_gmt] => 2021-05-28 16:09:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 2554
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:44:47
                            [post_date_gmt] => 2021-03-12 13:44:47
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:26:22
                            [post_modified_gmt] => 2021-05-17 13:26:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2554
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 2457
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:57
                            [post_date_gmt] => 2021-02-25 15:25:57
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:09:35
                            [post_modified_gmt] => 2021-05-17 13:09:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 2459
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:31
                            [post_date_gmt] => 2021-02-25 15:25:31
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:50:06
                            [post_modified_gmt] => 2021-06-01 09:50:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2459
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 2460
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:51
                            [post_date_gmt] => 2021-02-25 15:23:51
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:51
                            [post_modified_gmt] => 2021-02-25 15:23:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2460
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 2461
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:35
                            [post_date_gmt] => 2021-02-25 15:23:35
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:35
                            [post_modified_gmt] => 2021-02-25 15:23:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 2462
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:19
                            [post_date_gmt] => 2021-02-25 15:23:19
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:19
                            [post_modified_gmt] => 2021-02-25 15:23:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 2463
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:22:52
                            [post_date_gmt] => 2021-02-25 15:22:52
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:55:43
                            [post_modified_gmt] => 2021-06-01 09:55:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 2464
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:51
                            [post_date_gmt] => 2021-02-25 15:21:51
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:21:51
                            [post_modified_gmt] => 2021-02-25 15:21:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 2465
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:32
                            [post_date_gmt] => 2021-02-25 15:21:32
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 10:25:45
                            [post_modified_gmt] => 2021-05-27 10:25:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 2466
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:40
                            [post_date_gmt] => 2021-02-25 15:20:40
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 14:59:57
                            [post_modified_gmt] => 2021-06-21 14:59:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 2467
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:15
                            [post_date_gmt] => 2021-02-25 15:20:15
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:20:15
                            [post_modified_gmt] => 2021-02-25 15:20:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 2470
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:24:13
                            [post_date_gmt] => 2021-01-25 13:24:13
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:26:57
                            [post_modified_gmt] => 2021-05-17 13:26:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 2472
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:23:03
                            [post_date_gmt] => 2021-01-25 13:23:03
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:05
                            [post_modified_gmt] => 2021-05-17 13:27:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2472
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 2473
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:21:58
                            [post_date_gmt] => 2021-01-25 13:21:58
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:13
                            [post_modified_gmt] => 2021-05-17 13:27:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 2474
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:19:34
                            [post_date_gmt] => 2021-01-25 13:19:34
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 11:53:52
                            [post_modified_gmt] => 2021-07-22 11:53:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 2475
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:53
                            [post_date_gmt] => 2021-01-25 13:18:53
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:28
                            [post_modified_gmt] => 2021-05-17 13:27:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 2476
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:09
                            [post_date_gmt] => 2021-01-25 13:18:09
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:36
                            [post_modified_gmt] => 2021-05-17 13:27:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 2477
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:16:23
                            [post_date_gmt] => 2021-01-25 13:16:23
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:44
                            [post_modified_gmt] => 2021-05-17 13:27:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 2478
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:14:33
                            [post_date_gmt] => 2021-01-25 13:14:33
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 11:31:53
                            [post_modified_gmt] => 2021-06-17 11:31:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2478
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 2479
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:12:32
                            [post_date_gmt] => 2021-01-25 13:12:32
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 17:33:15
                            [post_modified_gmt] => 2021-06-01 17:33:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 2480
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:47
                            [post_date_gmt] => 2021-01-25 13:11:47
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:28:03
                            [post_modified_gmt] => 2021-05-17 13:28:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2480
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 2481
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:08
                            [post_date_gmt] => 2021-01-25 13:11:08
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 09:53:25
                            [post_modified_gmt] => 2021-06-17 09:53:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 2482
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:09:37
                            [post_date_gmt] => 2021-01-25 13:09:37
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-16 15:58:24
                            [post_modified_gmt] => 2021-06-16 15:58:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 2483
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:51
                            [post_date_gmt] => 2021-01-25 13:08:51
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:28:30
                            [post_modified_gmt] => 2021-05-17 13:28:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2483
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 2471
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:02
                            [post_date_gmt] => 2021-01-25 13:08:02
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-10 10:15:54
                            [post_modified_gmt] => 2021-06-10 10:15:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 3406
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:25:58
                            [post_date_gmt] => 2021-06-30 18:25:58
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:26:40
                            [post_modified_gmt] => 2021-06-30 18:26:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3406
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 3304
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:30:56
                            [post_date_gmt] => 2021-06-30 09:30:56
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 09:30:56
                            [post_modified_gmt] => 2021-06-30 09:30:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3304
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 3127
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:08:41
                            [post_date_gmt] => 2021-06-03 15:08:41
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:01:02
                            [post_modified_gmt] => 2021-06-04 08:01:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 3126
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:05:40
                            [post_date_gmt] => 2021-06-03 15:05:40
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:01:29
                            [post_modified_gmt] => 2021-06-04 08:01:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3126
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 3125
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:03:17
                            [post_date_gmt] => 2021-06-03 15:03:17
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:01:54
                            [post_modified_gmt] => 2021-06-04 08:01:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 3124
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:01:23
                            [post_date_gmt] => 2021-06-03 15:01:23
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:02:32
                            [post_modified_gmt] => 2021-06-04 08:02:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3124
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 3123
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:51:22
                            [post_date_gmt] => 2021-06-03 14:51:22
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 12:37:50
                            [post_modified_gmt] => 2021-07-21 12:37:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 3122
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:45:44
                            [post_date_gmt] => 2021-06-03 14:45:44
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:05:37
                            [post_modified_gmt] => 2021-06-04 08:05:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 3121
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:26:32
                            [post_date_gmt] => 2021-06-03 14:26:32
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:09:56
                            [post_modified_gmt] => 2021-06-04 08:09:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 3120
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:24:03
                            [post_date_gmt] => 2021-06-03 14:24:03
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:13:26
                            [post_modified_gmt] => 2021-06-04 08:13:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 3119
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:21:50
                            [post_date_gmt] => 2021-06-03 14:21:50
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 13:54:22
                            [post_modified_gmt] => 2021-06-07 13:54:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 2947
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:54:17
                            [post_date_gmt] => 2021-05-28 18:54:17
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 08:16:41
                            [post_modified_gmt] => 2021-06-02 08:16:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2947
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 2873
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:17:08
                            [post_date_gmt] => 2021-05-11 15:17:08
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-26 08:35:05
                            [post_modified_gmt] => 2021-05-26 08:35:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 2872
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:14:24
                            [post_date_gmt] => 2021-05-11 15:14:24
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 14:35:52
                            [post_modified_gmt] => 2021-06-07 14:35:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2872
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 2870
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:07:59
                            [post_date_gmt] => 2021-05-11 15:07:59
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-15 09:15:21
                            [post_modified_gmt] => 2021-06-15 09:15:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 2869
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:53:04
                            [post_date_gmt] => 2021-05-11 14:53:04
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 09:15:00
                            [post_modified_gmt] => 2021-05-14 09:15:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 2868
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:44:06
                            [post_date_gmt] => 2021-05-11 14:44:06
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 09:26:33
                            [post_modified_gmt] => 2021-05-14 09:26:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2868
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 2867
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:28:02
                            [post_date_gmt] => 2021-05-11 14:28:02
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2867
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:21:28
                            [post_modified_gmt] => 2021-06-01 09:21:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2867
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 2865
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:25:05
                            [post_date_gmt] => 2021-05-11 14:25:05
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 09:48:01
                            [post_modified_gmt] => 2021-05-14 09:48:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2865
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 2824
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:39:49
                            [post_date_gmt] => 2021-04-16 16:39:49
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:39:49
                            [post_modified_gmt] => 2021-04-16 16:39:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 2823
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:17:11
                            [post_date_gmt] => 2021-04-16 16:17:11
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:17:11
                            [post_modified_gmt] => 2021-04-16 16:17:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2823
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 2822
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:09:31
                            [post_date_gmt] => 2021-04-16 16:09:31
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:09:31
                            [post_modified_gmt] => 2021-04-16 16:09:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 2454
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:44:16
                            [post_date_gmt] => 2021-01-19 11:44:16
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:43:04
                            [post_modified_gmt] => 2021-05-27 09:43:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2454
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 2452
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:41:19
                            [post_date_gmt] => 2021-01-19 11:41:19
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 12:14:43
                            [post_modified_gmt] => 2021-06-02 12:14:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 2450
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:04:23
                            [post_date_gmt] => 2021-01-19 11:04:23
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:47:15
                            [post_modified_gmt] => 2021-05-27 09:47:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 2449
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:47:27
                            [post_date_gmt] => 2021-01-19 10:47:27
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:47:52
                            [post_modified_gmt] => 2021-05-27 09:47:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 2448
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:24:45
                            [post_date_gmt] => 2021-01-19 10:24:45
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:49:00
                            [post_modified_gmt] => 2021-05-27 09:49:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 2445
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:31:14
                            [post_date_gmt] => 2021-01-19 09:31:14
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 08:28:27
                            [post_modified_gmt] => 2021-07-07 08:28:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2445
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 2444
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:27:20
                            [post_date_gmt] => 2021-01-19 09:27:20
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:33:58
                            [post_modified_gmt] => 2021-05-27 09:33:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 2443
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:14:03
                            [post_date_gmt] => 2021-01-19 09:14:03
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:34:37
                            [post_modified_gmt] => 2021-05-27 09:34:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 2442
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:56:32
                            [post_date_gmt] => 2021-01-19 06:56:32
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 08:30:33
                            [post_modified_gmt] => 2021-07-07 08:30:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 2441
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:48:04
                            [post_date_gmt] => 2021-01-19 06:48:04
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:36:53
                            [post_modified_gmt] => 2021-05-27 09:36:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 2440
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:45:33
                            [post_date_gmt] => 2021-01-19 06:45:33
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:37:25
                            [post_modified_gmt] => 2021-05-27 09:37:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2440
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 2425
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:33
                            [post_date_gmt] => 2020-12-14 15:02:33
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-22 12:13:42
                            [post_modified_gmt] => 2021-01-22 12:13:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2425
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 2426
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:08
                            [post_date_gmt] => 2020-12-14 15:02:08
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 18:47:49
                            [post_modified_gmt] => 2021-06-01 18:47:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 2424
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:01:40
                            [post_date_gmt] => 2020-12-14 15:01:40
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 08:18:09
                            [post_modified_gmt] => 2021-06-09 08:18:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 2422
                            [post_author] => 5
                            [post_date] => 2020-12-14 14:59:29
                            [post_date_gmt] => 2020-12-14 14:59:29
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 11:33:16
                            [post_modified_gmt] => 2021-06-21 11:33:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 128
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 3436
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:48:49
                    [post_date_gmt] => 2021-07-01 03:48:49
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 11:01:08
                    [post_modified_gmt] => 2021-07-22 11:01:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 128
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => b1050dec43e5eb51fb39662feaeb2b86
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 3436
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:48:49
                    [post_date_gmt] => 2021-07-01 03:48:49
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 11:01:08
                    [post_modified_gmt] => 2021-07-22 11:01:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 3435
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:45:58
                    [post_date_gmt] => 2021-07-01 03:45:58
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:45:58
                    [post_modified_gmt] => 2021-07-01 03:45:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3435
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 3434
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:44:18
                    [post_date_gmt] => 2021-07-01 03:44:18
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:44:18
                    [post_modified_gmt] => 2021-07-01 03:44:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3434
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 3433
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:41:21
                    [post_date_gmt] => 2021-07-01 03:41:21
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:41:21
                    [post_modified_gmt] => 2021-07-01 03:41:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3433
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 3431
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:38:49
                    [post_date_gmt] => 2021-07-01 03:38:49
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:38:49
                    [post_modified_gmt] => 2021-07-01 03:38:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3431
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 3430
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:27:51
                    [post_date_gmt] => 2021-07-01 03:27:51
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 13:58:20
                    [post_modified_gmt] => 2021-07-22 13:58:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3430
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 3428
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:24:00
                    [post_date_gmt] => 2021-07-01 03:24:00
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:24:00
                    [post_modified_gmt] => 2021-07-01 03:24:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3428
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 3427
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:22:23
                    [post_date_gmt] => 2021-07-01 03:22:23
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:22:23
                    [post_modified_gmt] => 2021-07-01 03:22:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3427
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 3426
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:06:23
                    [post_date_gmt] => 2021-07-01 03:06:23
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:06:23
                    [post_modified_gmt] => 2021-07-01 03:06:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3426
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 3424
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:03:57
                    [post_date_gmt] => 2021-07-01 03:03:57
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:03:57
                    [post_modified_gmt] => 2021-07-01 03:03:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3424
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 3422
                    [post_author] => 6
                    [post_date] => 2021-07-01 02:58:21
                    [post_date_gmt] => 2021-07-01 02:58:21
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 15:32:57
                    [post_modified_gmt] => 2021-07-22 15:32:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3422
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 3421
                    [post_author] => 6
                    [post_date] => 2021-07-01 02:56:30
                    [post_date_gmt] => 2021-07-01 02:56:30
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 02:56:30
                    [post_modified_gmt] => 2021-07-01 02:56:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3421
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 3420
                    [post_author] => 6
                    [post_date] => 2021-07-01 02:52:05
                    [post_date_gmt] => 2021-07-01 02:52:05
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 02:52:05
                    [post_modified_gmt] => 2021-07-01 02:52:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3420
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 3406
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:25:58
                    [post_date_gmt] => 2021-06-30 18:25:58
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:26:40
                    [post_modified_gmt] => 2021-06-30 18:26:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3406
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 3372
                    [post_author] => 5
                    [post_date] => 2021-06-30 15:06:19
                    [post_date_gmt] => 2021-06-30 15:06:19
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 15:06:19
                    [post_modified_gmt] => 2021-06-30 15:06:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3372
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 3371
                    [post_author] => 5
                    [post_date] => 2021-06-30 15:03:10
                    [post_date_gmt] => 2021-06-30 15:03:10
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 15:03:10
                    [post_modified_gmt] => 2021-06-30 15:03:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3371
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 3370
                    [post_author] => 5
                    [post_date] => 2021-06-30 15:01:06
                    [post_date_gmt] => 2021-06-30 15:01:06
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 15:01:06
                    [post_modified_gmt] => 2021-06-30 15:01:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3370
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 3368
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:58:39
                    [post_date_gmt] => 2021-06-30 14:58:39
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:58:39
                    [post_modified_gmt] => 2021-06-30 14:58:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3368
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 3366
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:53:53
                    [post_date_gmt] => 2021-06-30 14:53:53
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:53:53
                    [post_modified_gmt] => 2021-06-30 14:53:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3366
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 3364
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:47:34
                    [post_date_gmt] => 2021-06-30 14:47:34
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:47:34
                    [post_modified_gmt] => 2021-06-30 14:47:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3364
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 3363
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:45:00
                    [post_date_gmt] => 2021-06-30 14:45:00
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:45:00
                    [post_modified_gmt] => 2021-06-30 14:45:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3363
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 3361
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:30:51
                    [post_date_gmt] => 2021-06-30 14:30:51
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:30:51
                    [post_modified_gmt] => 2021-06-30 14:30:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3361
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 3360
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:28:40
                    [post_date_gmt] => 2021-06-30 14:28:40
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:28:40
                    [post_modified_gmt] => 2021-06-30 14:28:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3360
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 3356
                    [post_author] => 5
                    [post_date] => 2021-06-30 13:53:23
                    [post_date_gmt] => 2021-06-30 13:53:23
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:53:23
                    [post_modified_gmt] => 2021-06-30 13:53:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 3354
                    [post_author] => 5
                    [post_date] => 2021-06-30 13:29:21
                    [post_date_gmt] => 2021-06-30 13:29:21
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:29:21
                    [post_modified_gmt] => 2021-06-30 13:29:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3354
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 3352
                    [post_author] => 5
                    [post_date] => 2021-06-30 13:24:49
                    [post_date_gmt] => 2021-06-30 13:24:49
                    [post_content] => 
                    [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:24:49
                    [post_modified_gmt] => 2021-06-30 13:24:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3352
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 3304
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:30:56
                    [post_date_gmt] => 2021-06-30 09:30:56
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 09:30:56
                    [post_modified_gmt] => 2021-06-30 09:30:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3304
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 3221
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:23:49
                    [post_date_gmt] => 2021-06-28 12:23:49
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:23:49
                    [post_modified_gmt] => 2021-06-28 12:23:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 3220
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:22:09
                    [post_date_gmt] => 2021-06-28 12:22:09
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:22:09
                    [post_modified_gmt] => 2021-06-28 12:22:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3220
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 3219
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:19:29
                    [post_date_gmt] => 2021-06-28 12:19:29
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:19:29
                    [post_modified_gmt] => 2021-06-28 12:19:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3219
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 3218
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:16:20
                    [post_date_gmt] => 2021-06-28 12:16:20
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:16:20
                    [post_modified_gmt] => 2021-06-28 12:16:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3218
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 3217
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:14:37
                    [post_date_gmt] => 2021-06-28 12:14:37
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:14:37
                    [post_modified_gmt] => 2021-06-28 12:14:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3217
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 3216
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:11:22
                    [post_date_gmt] => 2021-06-28 12:11:22
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:11:22
                    [post_modified_gmt] => 2021-06-28 12:11:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3216
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 3215
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:07:55
                    [post_date_gmt] => 2021-06-28 12:07:55
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:07:55
                    [post_modified_gmt] => 2021-06-28 12:07:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3215
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 3127
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:08:41
                    [post_date_gmt] => 2021-06-03 15:08:41
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:01:02
                    [post_modified_gmt] => 2021-06-04 08:01:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3127
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 3126
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:05:40
                    [post_date_gmt] => 2021-06-03 15:05:40
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:01:29
                    [post_modified_gmt] => 2021-06-04 08:01:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3126
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 3125
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:03:17
                    [post_date_gmt] => 2021-06-03 15:03:17
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:01:54
                    [post_modified_gmt] => 2021-06-04 08:01:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3125
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 3124
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:01:23
                    [post_date_gmt] => 2021-06-03 15:01:23
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:02:32
                    [post_modified_gmt] => 2021-06-04 08:02:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3124
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 3123
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:51:22
                    [post_date_gmt] => 2021-06-03 14:51:22
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 12:37:50
                    [post_modified_gmt] => 2021-07-21 12:37:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3123
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 3122
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:45:44
                    [post_date_gmt] => 2021-06-03 14:45:44
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:05:37
                    [post_modified_gmt] => 2021-06-04 08:05:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3122
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 3121
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:26:32
                    [post_date_gmt] => 2021-06-03 14:26:32
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:09:56
                    [post_modified_gmt] => 2021-06-04 08:09:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3121
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 3120
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:24:03
                    [post_date_gmt] => 2021-06-03 14:24:03
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:13:26
                    [post_modified_gmt] => 2021-06-04 08:13:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3120
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 3119
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:21:50
                    [post_date_gmt] => 2021-06-03 14:21:50
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 13:54:22
                    [post_modified_gmt] => 2021-06-07 13:54:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3119
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 2956
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:56:15
                    [post_date_gmt] => 2021-05-28 18:56:15
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:49:49
                    [post_modified_gmt] => 2021-06-02 08:49:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2956
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 2961
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:55:47
                    [post_date_gmt] => 2021-05-28 18:55:47
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:23:30
                    [post_modified_gmt] => 2021-06-02 09:23:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2961
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 2965
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:55:12
                    [post_date_gmt] => 2021-05-28 18:55:12
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 13:00:56
                    [post_modified_gmt] => 2021-06-08 13:00:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2965
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 2947
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:54:17
                    [post_date_gmt] => 2021-05-28 18:54:17
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:16:41
                    [post_modified_gmt] => 2021-06-02 08:16:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2947
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 2960
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:53:36
                    [post_date_gmt] => 2021-05-28 18:53:36
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:21:06
                    [post_modified_gmt] => 2021-06-02 09:21:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2960
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 2964
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:53:11
                    [post_date_gmt] => 2021-05-28 18:53:11
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:02:13
                    [post_modified_gmt] => 2021-06-02 08:02:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2964
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 2958
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:52:54
                    [post_date_gmt] => 2021-05-28 18:52:54
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:14:15
                    [post_modified_gmt] => 2021-06-02 09:14:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2958
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 2949
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:52:06
                    [post_date_gmt] => 2021-05-28 18:52:06
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-23 13:13:35
                    [post_modified_gmt] => 2021-06-23 13:13:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2949
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 2957
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:51:39
                    [post_date_gmt] => 2021-05-28 18:51:39
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:09:58
                    [post_modified_gmt] => 2021-06-02 09:09:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2957
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 2962
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:50:18
                    [post_date_gmt] => 2021-05-28 18:50:18
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:19:22
                    [post_modified_gmt] => 2021-06-02 09:19:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2962
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 2945
                    [post_author] => 6
                    [post_date] => 2021-05-28 14:03:27
                    [post_date_gmt] => 2021-05-28 14:03:27
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:51:28
                    [post_modified_gmt] => 2021-06-02 08:51:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2945
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 2909
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:13:58
                    [post_date_gmt] => 2021-05-19 15:13:58
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-16 15:39:30
                    [post_modified_gmt] => 2021-06-16 15:39:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 2908
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:08:05
                    [post_date_gmt] => 2021-05-19 15:08:05
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 12:18:00
                    [post_modified_gmt] => 2021-07-21 12:18:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 2907
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:46:20
                    [post_date_gmt] => 2021-05-19 14:46:20
                    [post_content] => 
                    [post_title] => Novavax – CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 14:10:32
                    [post_modified_gmt] => 2021-07-22 14:10:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 2893
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:40:45
                    [post_date_gmt] => 2021-05-19 14:40:45
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 08:56:01
                    [post_modified_gmt] => 2021-06-21 08:56:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 2892
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:30:23
                    [post_date_gmt] => 2021-05-14 19:30:23
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 15:13:39
                    [post_modified_gmt] => 2021-06-02 15:13:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 2890
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:14:07
                    [post_date_gmt] => 2021-05-14 19:14:07
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 12:49:25
                    [post_modified_gmt] => 2021-06-08 12:49:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 2889
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:09:07
                    [post_date_gmt] => 2021-05-14 19:09:07
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 19:09:07
                    [post_modified_gmt] => 2021-05-14 19:09:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 2888
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:01:08
                    [post_date_gmt] => 2021-05-14 19:01:08
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-20 12:23:46
                    [post_modified_gmt] => 2021-05-20 12:23:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2888
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [62] => WP_Post Object
                (
                    [ID] => 2886
                    [post_author] => 6
                    [post_date] => 2021-05-14 18:21:24
                    [post_date_gmt] => 2021-05-14 18:21:24
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 18:21:24
                    [post_modified_gmt] => 2021-05-14 18:21:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2886
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [63] => WP_Post Object
                (
                    [ID] => 2885
                    [post_author] => 5
                    [post_date] => 2021-05-14 18:17:37
                    [post_date_gmt] => 2021-05-14 18:17:37
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 18:17:37
                    [post_modified_gmt] => 2021-05-14 18:17:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [64] => WP_Post Object
                (
                    [ID] => 2873
                    [post_author] => 6
                    [post_date] => 2021-05-11 15:17:08
                    [post_date_gmt] => 2021-05-11 15:17:08
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-26 08:35:05
                    [post_modified_gmt] => 2021-05-26 08:35:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2873
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [65] => WP_Post Object
                (
                    [ID] => 2872
                    [post_author] => 6
                    [post_date] => 2021-05-11 15:14:24
                    [post_date_gmt] => 2021-05-11 15:14:24
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 14:35:52
                    [post_modified_gmt] => 2021-06-07 14:35:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2872
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [66] => WP_Post Object
                (
                    [ID] => 2870
                    [post_author] => 6
                    [post_date] => 2021-05-11 15:07:59
                    [post_date_gmt] => 2021-05-11 15:07:59
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-15 09:15:21
                    [post_modified_gmt] => 2021-06-15 09:15:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2870
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [67] => WP_Post Object
                (
                    [ID] => 2869
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:53:04
                    [post_date_gmt] => 2021-05-11 14:53:04
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 09:15:00
                    [post_modified_gmt] => 2021-05-14 09:15:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2869
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [68] => WP_Post Object
                (
                    [ID] => 2868
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:44:06
                    [post_date_gmt] => 2021-05-11 14:44:06
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 09:26:33
                    [post_modified_gmt] => 2021-05-14 09:26:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2868
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [69] => WP_Post Object
                (
                    [ID] => 2867
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:28:02
                    [post_date_gmt] => 2021-05-11 14:28:02
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 2867
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:21:28
                    [post_modified_gmt] => 2021-06-01 09:21:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2867
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [70] => WP_Post Object
                (
                    [ID] => 2865
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:25:05
                    [post_date_gmt] => 2021-05-11 14:25:05
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 09:48:01
                    [post_modified_gmt] => 2021-05-14 09:48:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2865
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [71] => WP_Post Object
                (
                    [ID] => 2824
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:39:49
                    [post_date_gmt] => 2021-04-16 16:39:49
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:39:49
                    [post_modified_gmt] => 2021-04-16 16:39:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [72] => WP_Post Object
                (
                    [ID] => 2823
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:17:11
                    [post_date_gmt] => 2021-04-16 16:17:11
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:17:11
                    [post_modified_gmt] => 2021-04-16 16:17:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2823
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [73] => WP_Post Object
                (
                    [ID] => 2822
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:09:31
                    [post_date_gmt] => 2021-04-16 16:09:31
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:09:31
                    [post_modified_gmt] => 2021-04-16 16:09:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [74] => WP_Post Object
                (
                    [ID] => 2821
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:55:04
                    [post_date_gmt] => 2021-04-16 12:55:04
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 12:55:04
                    [post_modified_gmt] => 2021-04-16 12:55:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2821
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [75] => WP_Post Object
                (
                    [ID] => 2820
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:44:14
                    [post_date_gmt] => 2021-04-16 12:44:14
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 11:55:37
                    [post_modified_gmt] => 2021-05-28 11:55:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [76] => WP_Post Object
                (
                    [ID] => 2819
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:12:32
                    [post_date_gmt] => 2021-04-16 12:12:32
                    [post_content] => 
                    [post_title] => Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 12:15:57
                    [post_modified_gmt] => 2021-04-16 12:15:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2819
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [77] => WP_Post Object
                (
                    [ID] => 2744
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:12:35
                    [post_date_gmt] => 2021-03-30 15:12:35
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:21:21
                    [post_modified_gmt] => 2021-05-17 13:21:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [78] => WP_Post Object
                (
                    [ID] => 2749
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:10:16
                    [post_date_gmt] => 2021-03-30 15:10:16
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:43:25
                    [post_modified_gmt] => 2021-06-01 09:43:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [79] => WP_Post Object
                (
                    [ID] => 2748
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:05:46
                    [post_date_gmt] => 2021-03-30 15:05:46
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 2748
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:21:40
                    [post_modified_gmt] => 2021-05-17 13:21:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [80] => WP_Post Object
                (
                    [ID] => 2740
                    [post_author] => 5
                    [post_date] => 2021-03-30 14:54:54
                    [post_date_gmt] => 2021-03-30 14:54:54
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:21:50
                    [post_modified_gmt] => 2021-05-17 13:21:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2740
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [81] => WP_Post Object
                (
                    [ID] => 2743
                    [post_author] => 5
                    [post_date] => 2021-03-24 15:11:40
                    [post_date_gmt] => 2021-03-24 15:11:40
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:22:13
                    [post_modified_gmt] => 2021-05-17 13:22:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [82] => WP_Post Object
                (
                    [ID] => 2742
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:37:07
                    [post_date_gmt] => 2021-03-24 13:37:07
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 14:14:47
                    [post_modified_gmt] => 2021-07-22 14:14:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [83] => WP_Post Object
                (
                    [ID] => 2741
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:32:55
                    [post_date_gmt] => 2021-03-24 13:32:55
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:22:24
                    [post_modified_gmt] => 2021-05-17 13:22:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [84] => WP_Post Object
                (
                    [ID] => 2739
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:12:14
                    [post_date_gmt] => 2021-03-24 13:12:14
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:22:33
                    [post_modified_gmt] => 2021-05-17 13:22:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [85] => WP_Post Object
                (
                    [ID] => 2738
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:04:24
                    [post_date_gmt] => 2021-03-24 13:04:24
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 09:03:59
                    [post_modified_gmt] => 2021-06-09 09:03:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2738
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [86] => WP_Post Object
                (
                    [ID] => 2737
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:00:46
                    [post_date_gmt] => 2021-03-24 13:00:46
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:23:04
                    [post_modified_gmt] => 2021-05-17 13:23:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [87] => WP_Post Object
                (
                    [ID] => 2736
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:15:15
                    [post_date_gmt] => 2021-03-23 18:15:15
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:23:17
                    [post_modified_gmt] => 2021-05-17 13:23:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [88] => WP_Post Object
                (
                    [ID] => 2735
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:05:28
                    [post_date_gmt] => 2021-03-23 18:05:28
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:23:28
                    [post_modified_gmt] => 2021-05-17 13:23:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2735
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [89] => WP_Post Object
                (
                    [ID] => 2734
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:01:22
                    [post_date_gmt] => 2021-03-23 18:01:22
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 17:12:58
                    [post_modified_gmt] => 2021-06-07 17:12:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [90] => WP_Post Object
                (
                    [ID] => 2543
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:15:58
                    [post_date_gmt] => 2021-03-12 18:15:58
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:24:40
                    [post_modified_gmt] => 2021-05-17 13:24:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [91] => WP_Post Object
                (
                    [ID] => 2540
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:12:48
                    [post_date_gmt] => 2021-03-12 18:12:48
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 13:52:44
                    [post_modified_gmt] => 2021-07-07 13:52:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [92] => WP_Post Object
                (
                    [ID] => 2541
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:11:14
                    [post_date_gmt] => 2021-03-12 18:11:14
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 16:06:34
                    [post_modified_gmt] => 2021-05-28 16:06:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [93] => WP_Post Object
                (
                    [ID] => 2542
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:21:07
                    [post_date_gmt] => 2021-03-12 14:21:07
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 15:59:01
                    [post_modified_gmt] => 2021-05-28 15:59:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [94] => WP_Post Object
                (
                    [ID] => 2544
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:16:06
                    [post_date_gmt] => 2021-03-12 14:16:06
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:14
                    [post_modified_gmt] => 2021-05-17 13:25:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [95] => WP_Post Object
                (
                    [ID] => 2545
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:14:38
                    [post_date_gmt] => 2021-03-12 14:14:38
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:23
                    [post_modified_gmt] => 2021-05-17 13:25:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [96] => WP_Post Object
                (
                    [ID] => 2546
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:13:16
                    [post_date_gmt] => 2021-03-12 14:13:16
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:35
                    [post_modified_gmt] => 2021-05-17 13:25:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2546
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [97] => WP_Post Object
                (
                    [ID] => 2547
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:58:55
                    [post_date_gmt] => 2021-03-12 13:58:55
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 10:39:30
                    [post_modified_gmt] => 2021-07-21 10:39:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [98] => WP_Post Object
                (
                    [ID] => 2548
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:55:59
                    [post_date_gmt] => 2021-03-12 13:55:59
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 09:42:06
                    [post_modified_gmt] => 2021-06-04 09:42:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2548
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [99] => WP_Post Object
                (
                    [ID] => 2549
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:50:41
                    [post_date_gmt] => 2021-03-12 13:50:41
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:58
                    [post_modified_gmt] => 2021-05-17 13:25:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [100] => WP_Post Object
                (
                    [ID] => 2553
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:47:42
                    [post_date_gmt] => 2021-03-12 13:47:42
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 16:09:05
                    [post_modified_gmt] => 2021-05-28 16:09:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [101] => WP_Post Object
                (
                    [ID] => 2554
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:44:47
                    [post_date_gmt] => 2021-03-12 13:44:47
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:26:22
                    [post_modified_gmt] => 2021-05-17 13:26:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2554
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [102] => WP_Post Object
                (
                    [ID] => 2457
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:25:57
                    [post_date_gmt] => 2021-02-25 15:25:57
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:09:35
                    [post_modified_gmt] => 2021-05-17 13:09:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [103] => WP_Post Object
                (
                    [ID] => 2459
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:25:31
                    [post_date_gmt] => 2021-02-25 15:25:31
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:50:06
                    [post_modified_gmt] => 2021-06-01 09:50:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2459
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [104] => WP_Post Object
                (
                    [ID] => 2460
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:51
                    [post_date_gmt] => 2021-02-25 15:23:51
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:51
                    [post_modified_gmt] => 2021-02-25 15:23:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2460
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [105] => WP_Post Object
                (
                    [ID] => 2461
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:35
                    [post_date_gmt] => 2021-02-25 15:23:35
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:35
                    [post_modified_gmt] => 2021-02-25 15:23:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [106] => WP_Post Object
                (
                    [ID] => 2462
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:19
                    [post_date_gmt] => 2021-02-25 15:23:19
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:19
                    [post_modified_gmt] => 2021-02-25 15:23:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [107] => WP_Post Object
                (
                    [ID] => 2463
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:22:52
                    [post_date_gmt] => 2021-02-25 15:22:52
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:55:43
                    [post_modified_gmt] => 2021-06-01 09:55:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [108] => WP_Post Object
                (
                    [ID] => 2464
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:51
                    [post_date_gmt] => 2021-02-25 15:21:51
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:21:51
                    [post_modified_gmt] => 2021-02-25 15:21:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [109] => WP_Post Object
                (
                    [ID] => 2465
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:32
                    [post_date_gmt] => 2021-02-25 15:21:32
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 10:25:45
                    [post_modified_gmt] => 2021-05-27 10:25:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [110] => WP_Post Object
                (
                    [ID] => 2466
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:40
                    [post_date_gmt] => 2021-02-25 15:20:40
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 14:59:57
                    [post_modified_gmt] => 2021-06-21 14:59:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [111] => WP_Post Object
                (
                    [ID] => 2467
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:15
                    [post_date_gmt] => 2021-02-25 15:20:15
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:20:15
                    [post_modified_gmt] => 2021-02-25 15:20:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [112] => WP_Post Object
                (
                    [ID] => 2470
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:24:13
                    [post_date_gmt] => 2021-01-25 13:24:13
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:26:57
                    [post_modified_gmt] => 2021-05-17 13:26:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [113] => WP_Post Object
                (
                    [ID] => 2472
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:23:03
                    [post_date_gmt] => 2021-01-25 13:23:03
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:05
                    [post_modified_gmt] => 2021-05-17 13:27:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2472
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [114] => WP_Post Object
                (
                    [ID] => 2473
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:21:58
                    [post_date_gmt] => 2021-01-25 13:21:58
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:13
                    [post_modified_gmt] => 2021-05-17 13:27:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [115] => WP_Post Object
                (
                    [ID] => 2474
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:19:34
                    [post_date_gmt] => 2021-01-25 13:19:34
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 11:53:52
                    [post_modified_gmt] => 2021-07-22 11:53:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [116] => WP_Post Object
                (
                    [ID] => 2475
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:18:53
                    [post_date_gmt] => 2021-01-25 13:18:53
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:28
                    [post_modified_gmt] => 2021-05-17 13:27:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [117] => WP_Post Object
                (
                    [ID] => 2476
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:18:09
                    [post_date_gmt] => 2021-01-25 13:18:09
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:36
                    [post_modified_gmt] => 2021-05-17 13:27:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [118] => WP_Post Object
                (
                    [ID] => 2477
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:16:23
                    [post_date_gmt] => 2021-01-25 13:16:23
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:44
                    [post_modified_gmt] => 2021-05-17 13:27:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [119] => WP_Post Object
                (
                    [ID] => 2478
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:14:33
                    [post_date_gmt] => 2021-01-25 13:14:33
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 11:31:53
                    [post_modified_gmt] => 2021-06-17 11:31:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2478
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [120] => WP_Post Object
                (
                    [ID] => 2479
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:12:32
                    [post_date_gmt] => 2021-01-25 13:12:32
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 17:33:15
                    [post_modified_gmt] => 2021-06-01 17:33:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [121] => WP_Post Object
                (
                    [ID] => 2480
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:11:47
                    [post_date_gmt] => 2021-01-25 13:11:47
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:28:03
                    [post_modified_gmt] => 2021-05-17 13:28:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2480
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [122] => WP_Post Object
                (
                    [ID] => 2481
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:11:08
                    [post_date_gmt] => 2021-01-25 13:11:08
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 09:53:25
                    [post_modified_gmt] => 2021-06-17 09:53:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [123] => WP_Post Object
                (
                    [ID] => 2482
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:09:37
                    [post_date_gmt] => 2021-01-25 13:09:37
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-16 15:58:24
                    [post_modified_gmt] => 2021-06-16 15:58:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [124] => WP_Post Object
                (
                    [ID] => 2483
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:08:51
                    [post_date_gmt] => 2021-01-25 13:08:51
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:28:30
                    [post_modified_gmt] => 2021-05-17 13:28:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2483
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [125] => WP_Post Object
                (
                    [ID] => 2471
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:08:02
                    [post_date_gmt] => 2021-01-25 13:08:02
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-10 10:15:54
                    [post_modified_gmt] => 2021-06-10 10:15:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [126] => WP_Post Object
                (
                    [ID] => 2454
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:44:16
                    [post_date_gmt] => 2021-01-19 11:44:16
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:43:04
                    [post_modified_gmt] => 2021-05-27 09:43:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2454
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [127] => WP_Post Object
                (
                    [ID] => 2452
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:41:19
                    [post_date_gmt] => 2021-01-19 11:41:19
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 12:14:43
                    [post_modified_gmt] => 2021-06-02 12:14:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [128] => WP_Post Object
                (
                    [ID] => 2450
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:04:23
                    [post_date_gmt] => 2021-01-19 11:04:23
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:47:15
                    [post_modified_gmt] => 2021-05-27 09:47:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [129] => WP_Post Object
                (
                    [ID] => 2449
                    [post_author] => 5
                    [post_date] => 2021-01-19 10:47:27
                    [post_date_gmt] => 2021-01-19 10:47:27
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:47:52
                    [post_modified_gmt] => 2021-05-27 09:47:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [130] => WP_Post Object
                (
                    [ID] => 2448
                    [post_author] => 5
                    [post_date] => 2021-01-19 10:24:45
                    [post_date_gmt] => 2021-01-19 10:24:45
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:49:00
                    [post_modified_gmt] => 2021-05-27 09:49:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [131] => WP_Post Object
                (
                    [ID] => 2445
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:31:14
                    [post_date_gmt] => 2021-01-19 09:31:14
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 08:28:27
                    [post_modified_gmt] => 2021-07-07 08:28:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2445
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [132] => WP_Post Object
                (
                    [ID] => 2444
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:27:20
                    [post_date_gmt] => 2021-01-19 09:27:20
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:33:58
                    [post_modified_gmt] => 2021-05-27 09:33:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [133] => WP_Post Object
                (
                    [ID] => 2443
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:14:03
                    [post_date_gmt] => 2021-01-19 09:14:03
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:34:37
                    [post_modified_gmt] => 2021-05-27 09:34:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [134] => WP_Post Object
                (
                    [ID] => 2442
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:56:32
                    [post_date_gmt] => 2021-01-19 06:56:32
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 08:30:33
                    [post_modified_gmt] => 2021-07-07 08:30:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [135] => WP_Post Object
                (
                    [ID] => 2441
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:48:04
                    [post_date_gmt] => 2021-01-19 06:48:04
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:36:53
                    [post_modified_gmt] => 2021-05-27 09:36:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [136] => WP_Post Object
                (
                    [ID] => 2440
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:45:33
                    [post_date_gmt] => 2021-01-19 06:45:33
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:37:25
                    [post_modified_gmt] => 2021-05-27 09:37:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2440
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [137] => WP_Post Object
                (
                    [ID] => 2425
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:02:33
                    [post_date_gmt] => 2020-12-14 15:02:33
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-22 12:13:42
                    [post_modified_gmt] => 2021-01-22 12:13:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2425
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [138] => WP_Post Object
                (
                    [ID] => 2426
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:02:08
                    [post_date_gmt] => 2020-12-14 15:02:08
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 18:47:49
                    [post_modified_gmt] => 2021-06-01 18:47:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [139] => WP_Post Object
                (
                    [ID] => 2424
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:01:40
                    [post_date_gmt] => 2020-12-14 15:01:40
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 08:18:09
                    [post_modified_gmt] => 2021-06-09 08:18:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [140] => WP_Post Object
                (
                    [ID] => 2422
                    [post_author] => 5
                    [post_date] => 2020-12-14 14:59:29
                    [post_date_gmt] => 2020-12-14 14:59:29
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 11:33:16
                    [post_modified_gmt] => 2021-06-21 11:33:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2422
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 1
    [has_agreement_filters] => 
    [has_any_agreement_filter] => Array
        (
        )

    [found_agreements] => 
    [has_provision_filters] => 
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Access to medicines
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [91] => WP_Term Object
                (
                    [term_id] => 91
                    [name] => Access to results
                    [slug] => access-results
                    [term_group] => 0
                    [term_taxonomy_id] => 91
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 16
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable or reasonable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [55] => WP_Term Object
                (
                    [term_id] => 55
                    [name] => Annexes
                    [slug] => annexes
                    [term_group] => 0
                    [term_taxonomy_id] => 55
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit/revenue sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [58] => WP_Term Object
                (
                    [term_id] => 58
                    [name] => Commercialization strategy
                    [slug] => commercialization-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 58
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 33
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [59] => WP_Term Object
                (
                    [term_id] => 59
                    [name] => Conflict of Interest
                    [slug] => conflict-of-interest
                    [term_group] => 0
                    [term_taxonomy_id] => 59
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [51] => WP_Term Object
                (
                    [term_id] => 51
                    [name] => Consortium structure & management
                    [slug] => consortium-structure
                    [term_group] => 0
                    [term_taxonomy_id] => 51
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 9
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [82] => WP_Term Object
                (
                    [term_id] => 82
                    [name] => Data management
                    [slug] => data-management
                    [term_group] => 0
                    [term_taxonomy_id] => 82
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 11
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [267] => WP_Term Object
                (
                    [term_id] => 267
                    [name] => Dispute resolution
                    [slug] => dispute-resolution
                    [term_group] => 0
                    [term_taxonomy_id] => 267
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [271] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effect of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Equitable access
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [83] => WP_Term Object
                (
                    [term_id] => 83
                    [name] => Exceptions and limitations to the confidentiality obligations
                    [slug] => exceptions-confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 83
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [93] => WP_Term Object
                (
                    [term_id] => 93
                    [name] => Exceptions or limitations to the IP ownership rules
                    [slug] => exceptions-ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 93
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 2
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [92] => WP_Term Object
                (
                    [term_id] => 92
                    [name] => Exploitation of results
                    [slug] => exploitation-results
                    [term_group] => 0
                    [term_taxonomy_id] => 92
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 13
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [103] => WP_Term Object
                (
                    [term_id] => 103
                    [name] => Funder step-in rights
                    [slug] => funder-step-in
                    [term_group] => 0
                    [term_taxonomy_id] => 103
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [57] => WP_Term Object
                (
                    [term_id] => 57
                    [name] => Global access plans
                    [slug] => global-access-plans
                    [term_group] => 0
                    [term_taxonomy_id] => 57
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnity / indemnification
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 17
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Information sharing & data safety
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => IP ownership & licensing
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [79] => WP_Term Object
                (
                    [term_id] => 79
                    [name] => Limitation of liability/damage
                    [slug] => limitation-of-liability
                    [term_group] => 0
                    [term_taxonomy_id] => 79
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 23
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [85] => WP_Term Object
                (
                    [term_id] => 85
                    [name] => Material transfer
                    [slug] => material-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 85
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [98] => WP_Term Object
                (
                    [term_id] => 98
                    [name] => Open data
                    [slug] => open-data
                    [term_group] => 0
                    [term_taxonomy_id] => 98
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [97] => WP_Term Object
                (
                    [term_id] => 97
                    [name] => Open sciences
                    [slug] => open-sciences
                    [term_group] => 0
                    [term_taxonomy_id] => 97
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [47] => WP_Term Object
                (
                    [term_id] => 47
                    [name] => Open sciences & open data
                    [slug] => open-science
                    [term_group] => 0
                    [term_taxonomy_id] => 47
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [54] => WP_Term Object
                (
                    [term_id] => 54
                    [name] => Other
                    [slug] => other
                    [term_group] => 0
                    [term_taxonomy_id] => 54
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Outbreak preparedness
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of background IP
                    [slug] => ownership-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 17
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [89] => WP_Term Object
                (
                    [term_id] => 89
                    [name] => Ownership of results
                    [slug] => ownership-results
                    [term_group] => 0
                    [term_taxonomy_id] => 89
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 29
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [266] => WP_Term Object
                (
                    [term_id] => 266
                    [name] => Pandemic Products
                    [slug] => pandemic-products
                    [term_group] => 0
                    [term_taxonomy_id] => 266
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment Structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of results
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 16
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [107] => WP_Term Object
                (
                    [term_id] => 107
                    [name] => Public health licenses
                    [slug] => public-health-licenses
                    [term_group] => 0
                    [term_taxonomy_id] => 107
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [96] => WP_Term Object
                (
                    [term_id] => 96
                    [name] => Publication
                    [slug] => publication
                    [term_group] => 0
                    [term_taxonomy_id] => 96
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 13
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [279] => WP_Term Object
                (
                    [term_id] => 279
                    [name] => Reporting Requirements
                    [slug] => reporting-requirements
                    [term_group] => 0
                    [term_taxonomy_id] => 279
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [278] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Roles & Responsibilities
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [108] => WP_Term Object
                (
                    [term_id] => 108
                    [name] => Sublicenses
                    [slug] => sublicensee
                    [term_group] => 0
                    [term_taxonomy_id] => 108
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 4
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Supply/Purchase of Products
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [62] => WP_Term Object
                (
                    [term_id] => 62
                    [name] => Survival
                    [slug] => survival
                    [term_group] => 0
                    [term_taxonomy_id] => 62
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 2
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => Use of background IP
                    [slug] => use-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 21
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Access to medicines
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [access-results] => WP_Term Object
                (
                    [term_id] => 91
                    [name] => Access to results
                    [slug] => access-results
                    [term_group] => 0
                    [term_taxonomy_id] => 91
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 16
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable or reasonable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [annexes] => WP_Term Object
                (
                    [term_id] => 55
                    [name] => Annexes
                    [slug] => annexes
                    [term_group] => 0
                    [term_taxonomy_id] => 55
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit/revenue sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 1
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [commercialization-strategy] => WP_Term Object
                (
                    [term_id] => 58
                    [name] => Commercialization strategy
                    [slug] => commercialization-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 58
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 33
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [conflict-of-interest] => WP_Term Object
                (
                    [term_id] => 59
                    [name] => Conflict of Interest
                    [slug] => conflict-of-interest
                    [term_group] => 0
                    [term_taxonomy_id] => 59
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [consortium-structure] => WP_Term Object
                (
                    [term_id] => 51
                    [name] => Consortium structure & management
                    [slug] => consortium-structure
                    [term_group] => 0
                    [term_taxonomy_id] => 51
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 9
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [data-management] => WP_Term Object
                (
                    [term_id] => 82
                    [name] => Data management
                    [slug] => data-management
                    [term_group] => 0
                    [term_taxonomy_id] => 82
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 11
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [dispute-resolution] => WP_Term Object
                (
                    [term_id] => 267
                    [name] => Dispute resolution
                    [slug] => dispute-resolution
                    [term_group] => 0
                    [term_taxonomy_id] => 267
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [donation] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effect of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Equitable access
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [exceptions-confidentiality] => WP_Term Object
                (
                    [term_id] => 83
                    [name] => Exceptions and limitations to the confidentiality obligations
                    [slug] => exceptions-confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 83
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [exceptions-ip-ownership] => WP_Term Object
                (
                    [term_id] => 93
                    [name] => Exceptions or limitations to the IP ownership rules
                    [slug] => exceptions-ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 93
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 2
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [exploitation-results] => WP_Term Object
                (
                    [term_id] => 92
                    [name] => Exploitation of results
                    [slug] => exploitation-results
                    [term_group] => 0
                    [term_taxonomy_id] => 92
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 13
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [funder-step-in] => WP_Term Object
                (
                    [term_id] => 103
                    [name] => Funder step-in rights
                    [slug] => funder-step-in
                    [term_group] => 0
                    [term_taxonomy_id] => 103
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 1
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [global-access-plans] => WP_Term Object
                (
                    [term_id] => 57
                    [name] => Global access plans
                    [slug] => global-access-plans
                    [term_group] => 0
                    [term_taxonomy_id] => 57
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 55
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Annexes
                    [parent_slug] => annexes
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnity / indemnification
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 17
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Information sharing & data safety
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => IP ownership & licensing
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [limitation-of-liability] => WP_Term Object
                (
                    [term_id] => 79
                    [name] => Limitation of liability/damage
                    [slug] => limitation-of-liability
                    [term_group] => 0
                    [term_taxonomy_id] => 79
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 23
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [material-transfer] => WP_Term Object
                (
                    [term_id] => 85
                    [name] => Material transfer
                    [slug] => material-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 85
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [open-data] => WP_Term Object
                (
                    [term_id] => 98
                    [name] => Open data
                    [slug] => open-data
                    [term_group] => 0
                    [term_taxonomy_id] => 98
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 10
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [open-sciences] => WP_Term Object
                (
                    [term_id] => 97
                    [name] => Open sciences
                    [slug] => open-sciences
                    [term_group] => 0
                    [term_taxonomy_id] => 97
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 8
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [open-science] => WP_Term Object
                (
                    [term_id] => 47
                    [name] => Open sciences & open data
                    [slug] => open-science
                    [term_group] => 0
                    [term_taxonomy_id] => 47
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [other] => WP_Term Object
                (
                    [term_id] => 54
                    [name] => Other
                    [slug] => other
                    [term_group] => 0
                    [term_taxonomy_id] => 54
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Outbreak preparedness
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 4
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [ownership-background-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of background IP
                    [slug] => ownership-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 17
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [ownership-results] => WP_Term Object
                (
                    [term_id] => 89
                    [name] => Ownership of results
                    [slug] => ownership-results
                    [term_group] => 0
                    [term_taxonomy_id] => 89
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 29
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [pandemic-products] => WP_Term Object
                (
                    [term_id] => 266
                    [name] => Pandemic Products
                    [slug] => pandemic-products
                    [term_group] => 0
                    [term_taxonomy_id] => 266
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment Structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of results
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 16
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [public-health-licenses] => WP_Term Object
                (
                    [term_id] => 107
                    [name] => Public health licenses
                    [slug] => public-health-licenses
                    [term_group] => 0
                    [term_taxonomy_id] => 107
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [publication] => WP_Term Object
                (
                    [term_id] => 96
                    [name] => Publication
                    [slug] => publication
                    [term_group] => 0
                    [term_taxonomy_id] => 96
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 47
                    [count] => 13
                    [filter] => raw
                    [parent_name] => Open sciences & open data
                    [parent_slug] => open-science
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [reporting-requirements] => WP_Term Object
                (
                    [term_id] => 279
                    [name] => Reporting Requirements
                    [slug] => reporting-requirements
                    [term_group] => 0
                    [term_taxonomy_id] => 279
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 2
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & Warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 16
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [roles-responsibilities] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Roles & Responsibilities
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 51
                    [count] => 3
                    [filter] => raw
                    [parent_name] => Consortium structure & management
                    [parent_slug] => consortium-structure
                )

            [sublicensee] => WP_Term Object
                (
                    [term_id] => 108
                    [name] => Sublicenses
                    [slug] => sublicensee
                    [term_group] => 0
                    [term_taxonomy_id] => 108
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 4
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Supply/Purchase of Products
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 18
                    [filter] => raw
                    [parent_name] => Access to medicines
                    [parent_slug] => access-to-medicines
                )

            [survival] => WP_Term Object
                (
                    [term_id] => 62
                    [name] => Survival
                    [slug] => survival
                    [term_group] => 0
                    [term_taxonomy_id] => 62
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 54
                    [count] => 0
                    [filter] => raw
                    [parent_name] => Other
                    [parent_slug] => other
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 49
                    [count] => 6
                    [filter] => raw
                    [parent_name] => Information sharing & data safety
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 2
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 15
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [use-background-ip] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => Use of background IP
                    [slug] => use-background-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 21
                    [filter] => raw
                    [parent_name] => IP ownership & licensing
                    [parent_slug] => ip-ownership
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
        )

)